Clinical trial · Observational
Early Pulmonary Dysfunction in Childhood Cancer Patients
Prospective Multicentre Cohort Study of Early Pulmonary Dysfunction in Childhood Cancer Patients (SWISS-Pearl Study)
NCT05427136CI-TRIAL-00110936SWISS-PearlrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This longitudinal, prospective, multicentre study is to monitor lung function prospectively in childhood cancer patients after diagnosis. The impact of cancer treatment on pulmonary dysfunction non-invasively using lung function, lung imaging and breath analysis as well as clinical symptoms using a questionnaire will be assessed at different time points.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pulmonary Dysfunction | — | UNRESOLVED | — |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Breath Analysis | Diagnostic Test | — | UNRESOLVED |
| Collection of genetic samples | Other | — | UNRESOLVED |
| Data collection for assessment of clinical parameters and cumulative doses to chemotherapy, radiation, surgery and HSCT | Other | — | UNRESOLVED |
| Lung function measurements | Diagnostic Test | — | UNRESOLVED |
| Magnetic resonance imaging (MRI) | Diagnostic Test | — | UNRESOLVED |
| Standardized interview to assess respiratory symptoms | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (8)
- measure
- Change in Forced expiratory volume in 1 second (FEV1)
- timeFrame
- At Baseline (start of therapy), at month 3 (during intensive treatment), at month 6-18 (end of intensive treatment), 12 months after end of intensive treatment,24 months after end of intensive treatment
- description
- Dynamic lung function parameter: Forced expiratory volume in 1 second (FEV1)
- measure
- Change in ratio of FEV1/forced vital capacity (FVC) for airway obstruction
- timeFrame
- At Baseline (start of therapy), at month 3 (during intensive treatment), at month 6-18 (end of intensive treatment), 12 months after end of intensive treatment,24 months after end of intensive treatment
- description
- Dynamic lung function parameter: ratio of FEV1/forced vital capacity (FVC) for airway obstruction
- measure
- Change in total lung capacity (TLC)
- timeFrame
- At Baseline (start of therapy), at month 3 (during intensive treatment), at month 6-18 (end of intensive treatment), 12 months after end of intensive treatment,24 months after end of intensive treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 4 Years
- Maximum age
- 22 Years
Show eligibility criteria text
Inclusion Criteria: * at least one of the following cancer treatments: * chest radiation * treatment with any kind of chemotherapy * hematopoietic stem cell transplantation (HSCT) * thoracic surgery * consent for Childhood Cancer Registry (ChCR) registration Exclusion Criteria: * no signed informed consent * Operation outside the chest area as only cancer treatment * Relapsed cancer (patients who develop relapse during the study will not be excluded) * In addition for MRI and lung function tests: * Subjects who are respiratory insufficient and cannot perform a lung function test (less than 92% O2 saturation; under O2 therapy) * Pregnant * MRI measurement not possible without sedation * Metal (e.g. pacemaker) in the body
References
Publications (0)
Data not yet available
No reference posted for this study.